ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2647

Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features

Holme Vestin1, Nina Oparina1, Elisabeth Skoglund1, Maija-Leena Eloranta1, Martina Frodlund2, Iva Gunnarsson3, Chrisopher Sjöwall2, Elisabet Svenungsson4, Lars Rönnblom1, Juliana Imgenberg-Kreuz1 and Dag Leonard1, 1Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

Meeting: ACR Convergence 2025

Keywords: Epigenetics, genetics, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 29, 2025

Title: Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

Session Type: Abstract Session

Session Time: 10:00AM-10:15AM

Background/Purpose: The aetiopathogenesis of SLE encompasses genetic and epigenetic factors, including hypomethylation of type I interferon (IFN) regulated genes (1) and the HLA-DRB1*03:01 haplotype, linked to C4A copy numbers and associated with anti-SSA/SSB antibodies (2). Further, a non-HLA SLE polygenic risk score (SLE-PRS) has been linked to a more severe disease (3). This study aimed to investigate the relationship between a methylation-based SLE risk score (MRS), an SLE-PRS, an HLA-DRB1*03:01 tag SNP, serum IFN-α levels and clinical phenotype.

Methods: DNA methylation levels in whole blood from patients fulfilling ≥4 ACR-82 criteria (n=547) and controls matched for age and sex (n=587) were investigated by the Illumina HM450K methylation array. Significant differentially methylated CpGs with a Δβ of ≥0.1 between cases and controls and located at independent genetic loci (n=17) were selected for calculation of the MRS. Clinical data were collected from patient charts. Serum IFN-α2 levels were measured in a subgroup of patients (n=85) using Simoa.We analysed if the MRS was associated with the SLE-PRS including 57 non-HLA SLE risk loci (3), with the HLA-DRB1*03:01 tag SNP rs1269852 and with levels of IFN-α using linear regression models. Associations between the MRS, SLE-PRS and HLA-DRB1*03:01 tag SNP and clinical variables were assessed applying logistic regression. Models were adjusted for age and sex, p< 0.05 was considered significant.

Results: The MRS was associated with high disease activity (SLEDAI >4 or SLAM >6 ) (OR=1.01, p=2.0×10-4), higher IFNα levels (Exp(B)=1.03, p=8.1×10-13) and low complement (OR=1.01, p=2.2×10-3), while the SLE-PRS was not (all p >0.05). Further, no significant correlation between the MRS and the SLE-PRS was observed (p >0.05).The MRS was associated with discoid rash (OR=1.02, p=3.5×10-4), hematologic criteria (OR=1.02, 1.6×10-7) and immunologic criteria (OR=1.01, p=1.4×10-4), while the SLE-PRS was associated with the nephritis (OR=1.19, p=0.04) and the immunologic criteria (OR=1.40, p=1.1×10-4). Further, the MRS, but not the SLE-PRS, associated with anti-SSA and anti-RNP antibodies (OR=1.03, p=1.1×10-12 and OR=1.02, p=8.2×10-11).The HLA-DRB1*03:01 tag SNP was significantly associated with higher MRS (B=7.22, p=8.6×10-4) and with anti-SSA and anti-SSB antibodies (OR 3.09 and 4.75, both p< 1x10-10).

Conclusion: The lack of correlation between the MRS and SLE-PRS suggests that they reflect distinct, yet complementary, aspects of SLE pathogenesis. The association between the MRS, high disease activity, higher levels of IFN-α2 in serum, anti-SSA antibodies and the HLA-DRB1*03:01 tag SNP implies that an epigenetic predisposition for IFN-α signalling might be of particular importance in HLA-DRB1*03:01 positive patients. These results underscore the relevance of integrating epigenetic profiling with genetic data to better understand disease heterogeneity and mechanisms in SLE. References1. Araki Y, et al. Int J Mol Sci. 20242. Lundtoft C, et al. Arthritis Rheumatol. 20223. Reid S, et al. Ann Rheum Dis. 2020


Disclosures: H. Vestin: None; N. Oparina: None; E. Skoglund: None; M. Eloranta: None; M. Frodlund: None; I. Gunnarsson: None; C. Sjöwall: Bristol-Myers Squibb(BMS), 3; E. Svenungsson: AstraZeneca, 11, Pfizer, 11; L. Rönnblom: AstraZeneca, 6, Biogen, 2; J. Imgenberg-Kreuz: None; D. Leonard: None.

To cite this abstract in AMA style:

Vestin H, Oparina N, Skoglund E, Eloranta M, Frodlund M, Gunnarsson I, Sjöwall C, Svenungsson E, Rönnblom L, Imgenberg-Kreuz J, Leonard D. Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/unlinked-paths-to-sle-divergent-associations-of-dna-methylation-and-polygenic-risk-scores-with-sle-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unlinked-paths-to-sle-divergent-associations-of-dna-methylation-and-polygenic-risk-scores-with-sle-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology